AVIR
Company Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 351.37M | 48.63M | 0 | 0 |
| Net Income | (158.35M) | (168.38M) | (135.96M) | (115.91M) | 121.19M | (10.95M) | (13.46M) | (9.06M) |
| EPS | -1.94 | -2.00 | -1.63 | -1.39 | 1.46 | -0.13 | -0.16 | -0.90 |
| Free Cash Flow | (132.03M) | (135.50M) | (85.39M) | (122.92M) | (87.01M) | 296.71M | (12.82M) | (7.92M) |
| FCF / Share | -1.62 | -1.61 | -1.02 | -1.48 | -1.05 | 3.60 | -0.16 | -0.78 |
| Operating CF | (132.03M) | (135.50M) | (85.39M) | (120.98M) | (87.00M) | 296.73M | (12.81M) | (7.91M) |
| Total Assets | 315.22M | 464.67M | 594.97M | 666.71M | 772.89M | 863.63M | 22.07M | 34.86M |
| Total Debt | 843,000 | 1.64M | 2.40M | 3.12M | 197,000 | 0 | 0 | 0 |
| Cash & Equiv | 95.71M | 64.70M | 143.82M | 646.71M | 764.38M | 850.12M | 21.66M | 34.49M |
| Book Value | 275.43M | 438.87M | 555.19M | 640.57M | 710.08M | 547.80M | 19.54M | (36.16M) |
| Return on Equity | -0.57 | -0.38 | -0.24 | -0.18 | 0.17 | -0.02 | -0.69 | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (32.93M) | (45.44M) | (44.87M) | (42.05M) | (37.16M) | (34.27M) | (33.54M) | (31.15M) | (40.52M) | (63.17M) | (39.16M) | (33.14M) |
| EPS | -0.41 | -0.57 | -0.57 | -0.53 | -0.44 | -0.40 | -0.40 | -0.37 | -0.48 | -0.75 | -0.47 | -0.40 |
| Free Cash Flow | (37.08M) | (46.39M) | (28.22M) | (40.38M) | (32.87M) | (30.56M) | (30.40M) | (23.04M) | (42.20M) | (39.87M) | (21.83M) | (17.59M) |
| FCF / Share | -0.46 | -0.59 | -0.36 | -0.51 | -0.39 | -0.36 | -0.36 | -0.27 | -0.50 | -0.48 | -0.26 | -0.21 |
| Operating CF | (37.08M) | (46.39M) | (28.22M) | (40.38M) | (32.87M) | (30.56M) | (30.40M) | (23.04M) | (42.20M) | (39.87M) | (21.83M) | (17.59M) |
| Total Assets | 232.28M | 267.08M | 315.22M | 342.96M | 391.61M | 439.96M | 464.67M | 490.96M | 510.38M | 553.03M | 594.97M | 608.08M |
| Total Debt | 424,000 | 634,000 | 843,000 | 1.04M | 1.25M | 1.45M | 1.64M | 1.83M | 2.02M | 2.21M | 2.40M | 2.58M |
| Cash & Equiv | 76.55M | 79.32M | 95.71M | 77.34M | 87.72M | 119.39M | 64.70M | 98.46M | 243.39M | 160.91M | 143.82M | 137.89M |
| Book Value | 204.16M | 233.71M | 275.43M | 315.78M | 364.42M | 411.08M | 438.87M | 458.52M | 476.47M | 504.37M | 555.19M | 581.73M |
| Return on Equity | -0.16 | -0.19 | -0.16 | -0.13 | -0.10 | -0.08 | -0.08 | -0.07 | -0.09 | -0.13 | -0.07 | -0.06 |
